Therapeutic Evaluation of Syrup Nexoliv™ for Liver Health Support
Abstract
Background: Liver disorders, ranging from hepatitis to cirrhosis, are prevalent globally due to infections, toxins, and metabolic imbalances. Traditional medicine offers numerous herbal formulations known for their hepatoprotective properties. Syrup NexolivTM is a polyherbal formulation composed of 23 medicinal plants traditionally recognized for liver protection, detoxification, and overall hepatobiliary support. This study evaluates the hepatoprotective potential of Syrup Nexoliv (SN) based on its rich phytoconstituents.
Objective: To assess the hepatoprotective effect of Syrup Nexoliv through its pharmacologically active ingredients, focusing on their synergistic roles in liver health.
Methods: Syrup Nexoliv contains key hepatoprotective herbs such as Kalmegh (Andrographis paniculata), Kutki (Picrorhiza kurroa), Punarnava (Boerhavia diffusa), and Bhui Amla (Phyllanthus niruri), known for their anti-inflammatory, antioxidant, and detoxifying properties. The formulation was evaluated through literature-based evidence highlighting individual and combined therapeutic effects of its components on hepatic cells, liver enzymes, and oxidative stress parameters.
Results: Phytochemical analysis of the ingredients revealed the presence of bioactive compounds such as andrographolides, picrosides, berberine, and glycyrrhizin, which exhibit hepatoprotective, anti-inflammatory, and antioxidant actions. These compounds help in stabilizing hepatic cell membranes, reducing elevated liver enzymes, enhancing bile secretion, and protecting against hepatotoxins. Herbal ingredients like Gilo (Tinospora cordifolia) and Mulethi (Glycyrrhiza glabra) further contribute to immune modulation and liver tissue regeneration. Collectively, these herbs demonstrate a synergistic effect in managing liver dysfunction and supporting hepatic detoxification processes.
Conclusion: Syrup Nexoliv, with its comprehensive blend of hepatoprotective herbs, presents a promising natural therapeutic option for preventing and managing liver disorders. Further clinical studies are warranted to validate its efficacy and safety in liver disease patients, along with its potential role as an adjunct to conventional hepatoprotective therapies.
Keywords: Liver disorders, herbal formulations, Syrup Nexoliv
Keywords:
Liver disorders, herbal formulations, Syrup NexolivDOI
https://doi.org/10.22270/jddt.v15i5.7121References
1. Sina I. Al qanoon fit tib. (Urdu Translation by Ghulam Hussain Kantoori) Vol. 3. New Delhi: Idara Kitabulshifa; 2010. p. 854-64.
2. Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017 Nov 6;27(21):R1147-R1151. https://doi.org/10.1016/j.cub.2017.09.019 PMid:29112863 PMCid:PMC5897118
3. Fritsche K, Ziková-Kloas A, Marx-Stoelting P, Braeuning A. Metabolism-Disrupting Chemicals Affecting the Liver: Screening, Testing, and Molecular Pathway Identification. Int J Mol Sci. 2023 Jan 31;24(3):2686. https://doi.org/10.3390/ijms24032686 PMid:36769005 PMCid:PMC9916672
4. Osna NA, Donohue TM Jr, Kharbanda KK. Alcoholic Liver Disease: Pathogenesis and Current Management. Alcohol Res. 2017;38(2):147-161.
5. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023 Aug;79(2):516-537. https://doi.org/10.1016/j.jhep.2023.03.017 PMid:36990226
6. Hong M, Li S, Tan HY, Wang N, Tsao SW, Feng Y. Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future Prospects. Int J Mol Sci. 2015 Dec 2;16(12):28705-45. https://doi.org/10.3390/ijms161226126 PMid:26633388 PMCid:PMC4691073
7. Yuan H, Ma Q, Ye L, Piao G. The Traditional Medicine and Modern Medicine from Natural Products. Molecules. 2016 Apr 29;21(5):559. https://doi.org/10.3390/molecules21050559 PMid:27136524 PMCid:PMC6273146
8. Ali M, Khan T, Fatima K, Ali QUA, Ovais M, Khalil AT, Ullah I, Raza A, Shinwari ZK, Idrees M. Selected hepatoprotective herbal medicines: Evidence from ethnomedicinal applications, animal models, and possible mechanism of actions. Phytother Res. 2018 Feb;32(2):199-215. https://doi.org/10.1002/ptr.5957 PMid:29047177 PMCid:PMC7167792
9. Chturvedi GN, Tomar GS, Tiwari SK, Singh KP. Clinical studies on kalmegh (andrographis paniculata nees) in infective hepatitis. Anc Sci Life. 1983 Apr;2(4):208-15.
10. Trivedi NP, Rawal UM, Patel BP. Hepatoprotective effect of andrographolide against hexachlorocyclohexane-induced oxidative injury. Integr Cancer Ther. 2007 Sep;6(3):271-80. https://doi.org/10.1177/1534735407305985 PMid:17761640
11. Raut A, Dhami-Shah H, Phadke A, Shindikar A, Udipi S, Joshi J, Vaidya R, Vaidya ADB. Picrorhiza kurroa, Royle ex Benth:Traditional uses, phytopharmacology, and translational potential in therapy of fatty liver disease. J Ayurveda Integr Med. 2023 Jan-Feb;14(1):100558. https://doi.org/10.1016/j.jaim.2022.100558 PMid:35659739 PMCid:PMC10105242
12. Sowjanya K, Girish C, Bammigatti C, Prasanna Lakshmi NC. Efficacy of Phyllanthus niruri on improving liver functions in patients with alcoholic hepatitis: A double-blind randomized controlled trial. Indian J Pharmacol. 2021 Nov-Dec;53(6):448-456. https://doi.org/10.4103/ijp.IJP_540_20 PMid:34975132 PMCid:PMC8764976
13. Tai CJ, Choong CY, Shi YC, Lin YC, Wang CW, Lee BH, Tai CJ. Solanum nigrum Protects against Hepatic Fibrosis via Suppression of Hyperglycemia in High-Fat/Ethanol Diet-Induced Rats. Molecules. 2016 Feb 25;21(3):269. https://doi.org/10.3390/molecules21030269 PMid:26927042 PMCid:PMC6274119
14. Chang JJ, Chung DJ, Lee YJ, Wen BH, Jao HY, Wang CJ. Solanum nigrum Polyphenol Extracts Inhibit Hepatic Inflammation, Oxidative Stress, and Lipogenesis in High-Fat-Diet-Treated Mice. J Agric Food Chem. 2017 Oct 25;65(42):9255-9265. https://doi.org/10.1021/acs.jafc.7b03578 PMid:28982243
15. Keshavarzi A, Akrami R, Zarshenas MM, Zareie S, Ghadimi T, Najafi A, Rostami Chijan M, Dehghan A, Zarenezhad E. Evaluation of the Effect of Cichorium intybus L. on the Liver Enzymes in Burn Patients: A Randomized Double-Blind Clinical Trial. Int J Clin Pract. 2024 Jan 11;2024:1016247. https://doi.org/10.1155/2024/1016247 PMid:38239768 PMCid:PMC10796187
16. Fakher S, Karbalay-Doust S, Noorafshan A, Seghatoleslam A. The Ameliorative Impact of Cichorium intybus L. Distillate on Reproductive Parameters in Male Mice. Iran J Med Sci. 2023 Nov 1;48(6):591-599. doi: https://doi.org/10.30476/IJMS.2023.96653.2826 .
17. Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y. The Role of Oxidative Stress and Antioxidants in Liver Diseases. Int J Mol Sci. 2015 Nov 2;16(11):26087-124. https://doi.org/10.3390/ijms161125942 PMid:26540040 PMCid:PMC4661801
18. Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig Dis Sci. 2005 Oct;50(10):1807-12. https://doi.org/10.1007/s10620-005-2942-9 PMid:16187178
19. Hora S, Wuestefeld T. Liver Injury and Regeneration: Current Understanding, New Approaches, and Future Perspectives. Cells. 2023 Aug 22;12(17):2129. https://doi.org/10.3390/cells12172129 PMid:37681858 PMCid:PMC10486351
20. Barouki R, Samson M, Blanc EB, Colombo M, Zucman-Rossi J, Lazaridis KN, Miller GW, Coumoul X. The exposome and liver disease - how environmental factors affect liver health. J Hepatol. 2023 Aug;79(2):492-505. https://doi.org/10.1016/j.jhep.2023.02.034 PMid:36889360 PMCid:PMC10448911
21. Belete D, Kassaw D, Andualem T. Prevalence of Hepatitis B and Hepatitis C Viral Infections and Their Associated Factors among Diabetic Patients Visiting Debre Tabor Referral Hospital, Northwest Ethiopia, 2021: A Cross-Sectional Study. Can J Gastroenterol Hepatol. 2023 Nov 17;2023:5077706. https://doi.org/10.1155/2023/5077706 PMid:38021268 PMCid:PMC10673667
22. Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):20160274. doi: 10.1098/rstb.2016.0274. Erratum in: Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):20170339. https://doi.org/10.1098/rstb.2017.0339 PMid:29158320 PMCid:PMC5717445
23. Osna NA, Donohue TM Jr, Kharbanda KK. Alcoholic Liver Disease: Pathogenesis and Current Management. Alcohol Res. 2017;38(2):147-161.
24. Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, Kassir R, Singhal R, Mahawar K, Ramnarain D. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022 Mar 14;22(1):63. https://doi.org/10.1186/s12902-022-00980-1 PMid:35287643 PMCid:PMC8919523
25. Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, Devarbhavi H, Merz M, Lucena MI, Kaplowitz N, Aithal GP. Drug-induced liver injury. Nat Rev Dis Primers. 2019 Aug 22;5(1):58. https://doi.org/10.1038/s41572-019-0105-0 PMid:31439850
26. Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol. 2015 Jan 7;21(1):60-83. https://doi.org/10.3748/wjg.v21.i1.60 PMid:25574080 PMCid:PMC4284362
27. Allameh A, Niayesh-Mehr R, Aliarab A, Sebastiani G, Pantopoulos K. Oxidative Stress in Liver Pathophysiology and Disease. Antioxidants (Basel). 2023 Aug 22;12(9):1653. https://doi.org/10.3390/antiox12091653 PMid:37759956 PMCid:PMC10525124
28. Khan MA. Akseer Azam. (Urdu translation by Kabeeruddin M). New Delhi: Idara kitabul shifa; 2011.p. 481-98.
29. Tabri AHAM. Moalajate Bukhratia. Vol. 3. New Delhi: C.C.R.U.M; 1997.
30. Ahmed NZ, Alam MA, Sheeraz M. Concept and Management of Fatty Liver Disease in Unani Medicine Vis-A-Vis Conventional Medicine-A Review. Spatula DD. 2014;4(4):233-41. https://doi.org/10.5455/spatula.20141113043401
31. Bruha R, Dvorak K, Petrtyl J. Alcoholic liver disease. World J Hepatol. 2012 Mar 27;4(3):81-90. https://doi.org/10.4254/wjh.v4.i3.81 PMid:22489260 PMCid:PMC3321494
32. Beier JI, Arteel GE. Environmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns. Acta Pharm Sin B. 2021 Dec;11(12):3768-3778. https://doi.org/10.1016/j.apsb.2021.09.005 PMid:35024305 PMCid:PMC8727918
33. David S, Hamilton JP. Drug-induced Liver Injury. US Gastroenterol Hepatol Rev. 2010 Jan 1;6:73-80.
34. Parlar YE, Ayar SN, Cagdas D, Balaban YH. Liver immunity, autoimmunity, and inborn errors of immunity. World J Hepatol. 2023 Jan 27;15(1):52-67. https://doi.org/10.4254/wjh.v15.i1.52 PMid:36744162 PMCid:PMC9896502
35. Pei Y, Goh GB. Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease. Gut Liver. 2025 Jan 15;19(1):8-18. https://doi.org/10.5009/gnl240407 PMid:39774124 PMCid:PMC11736312
36. Datta S, Aggarwal D, Sehrawat N, Yadav M, Sharma V, Sharma A, Zghair AN, Dhama K, Sharma A, Kumar V, Sharma AK. Hepatoprotective effects of natural drugs: Current trends, scope, relevance and future perspectives. Phytomedicine. 2023 Dec 1;121:155100. https://doi.org/10.1016/j.phymed.2023.155100 PMid:37801892
37. Read AE. Some clinical features of liver cell failure: an appraisal of their causes. Gut. 1978 Jun;19(6):543-8. https://doi.org/10.1136/gut.19.6.543 PMid:355067 PMCid:PMC1412018
38. Sharma A, Nagalli S. Chronic Liver Disease. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. PMID: 32119484.
39. Basaranoglu M, Neuschwander-Tetri BA. Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. Gastroenterol Hepatol (N Y). 2006 Apr;2(4):282-291.
40. Swain MG. Fatigue in liver disease: pathophysiology and clinical management. Can J Gastroenterol. 2006 Mar;20(3):181-8. https://doi.org/10.1155/2006/624832 PMid:16550262 PMCid:PMC2582971
41. Kalaitzakis E. Gastrointestinal dysfunction in liver cirrhosis. World J Gastroenterol. 2014 Oct 28;20(40):14686-95. https://doi.org/10.3748/wjg.v20.i40.14686 PMid:25356031 PMCid:PMC4209534
42. Liu Y, Zhao Y, Gao X, Liu J, Ji F, Hsu YC, Li Z, Nguyen MH. Recognizing skin conditions in patients with cirrhosis: a narrative review. Ann Med. 2022 Dec;54(1):3017-3029. https://doi.org/10.1080/07853890.2022.2138961 PMid:36308406 PMCid:PMC9629063
43. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138-147. https://doi.org/10.1093/gastro/gox013 PMid:28533911 PMCid:PMC5421503
44. Bhandari A, Mahajan R. Skin Changes in Cirrhosis. J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1215-1224. https://doi.org/10.1016/j.jceh.2021.12.013 PMid:35814509 PMCid:PMC9257870
45. Grant DM. Detoxification pathways in the liver. J Inherit Metab Dis. 1991;14(4):421-30. https://doi.org/10.1007/BF01797915 PMid:1749210
46. Roerecke M, Vafaei A, Hasan OSM, Chrystoja BR, Cruz M, Lee R, Neuman MG, Rehm J. Alcohol Consumption and Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019 Oct;114(10):1574-1586. https://doi.org/10.14309/ajg.0000000000000340 PMid:31464740 PMCid:PMC6776700
47. Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016 Mar 17;1(2):e000042. https://doi.org/10.1136/esmoopen-2016-000042 PMid:27843598 PMCid:PMC5070280
48. Nobili V, Carter-Kent C, Feldstein AE. The role of lifestyle changes in the management of chronic liver disease. BMC Med. 2011 Jun 6;9:70. https://doi.org/10.1186/1741-7015-9-70 PMid:21645344 PMCid:PMC3127780
49. Bhadoria AS, Mohapatra A, Gupta R, Chawla YK, Kant R, Nundy S. Preventive hepatology: An ounce of prevention or pounds of cure to curb liver diseases. J Family Med Prim Care. 2023 Mar;12(3):419-421. https://doi.org/10.4103/jfmpc.jfmpc_2225_22 PMid:37122647 PMCid:PMC10131973
50. Romero-Gómez M, Zelber-Sagi S, Martín F, Bugianesi E, Soria B. Nutrition could prevent or promote non-alcoholic fatty liver disease: an opportunity for intervention. BMJ. 2023 Oct 9;383:e075179. https://doi.org/10.1136/bmj-2023-075179 PMid:37813416 PMCid:PMC10561058
51. Henney AE, Gillespie CS, Alam U, Hydes TJ, Cuthbertson DJ. Ultra-Processed Food Intake Is Associated with Non-Alcoholic Fatty Liver Disease in Adults: A Systematic Review and Meta-Analysis. Nutrients. 2023 May 10;15(10):2266. https://doi.org/10.3390/nu15102266 PMid:37242149 PMCid:PMC10224355
52. Berná G, Romero-Gomez M. The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management. Liver Int. 2020 Feb;40 Suppl 1:102-108. https://doi.org/10.1111/liv.14360 PMid:32077594
53. Popkin BM, D'Anci KE, Rosenberg IH. Water, hydration, and health. Nutr Rev. 2010 Aug;68(8):439-58. https://doi.org/10.1111/j.1753-4887.2010.00304.x PMid:20646222 PMCid:PMC2908954
54. Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD003620. https://doi.org/10.1002/14651858.CD003620
55. Malik A, Kardashian AA, Zakharia K, Bowlus CL, Tabibian JH. Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist. Liver Res. 2019 Jun;3(2):118-127. https://doi.org/10.1016/j.livres.2019.04.001 PMid:32042471 PMCid:PMC7008979
56. Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol. 2014 May 27;6(5):263-73https://doi.org/10.4254/wjh.v6.i5.263 PMid:24868320 PMCid:PMC4033284
57. Stevanović J, Beleza J, Coxito P, Ascensão A, Magalhães J. Physical exercise and liver "fitness": Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease. Mol Metab. 2020 Feb;32:1-14. https://doi.org/10.1016/j.molmet.2019.11.015 PMid:32029220 PMCid:PMC6931125
58. Barrón-Cabrera E, Soria-Rodríguez R, Amador-Lara F, Martínez-López E. Physical Activity Protocols in Non-Alcoholic Fatty Liver Disease Management: A Systematic Review of Randomized Clinical Trials and Animal Models. Healthcare (Basel). 2023 Jul 10;11(14):1992. https://doi.org/10.3390/healthcare11141992 PMid:37510432 PMCid:PMC10379178
59. Migueres M, Lhomme S, Izopet J. Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment. Viruses. 2021 Sep 22;13(10):1900. https://doi.org/10.3390/v13101900 PMid:34696330 PMCid:PMC8540458
60. Fallucca A, Restivo V, Sgariglia MC, Roveta M, Trucchi C. Hepatitis a Vaccine as Opportunity of Primary Prevention for Food Handlers: A Narrative Review. Vaccines (Basel). 2023 Jul 21;11(7):1271. https://doi.org/10.3390/vaccines11071271 PMid:37515087 PMCid:PMC10383099
61. Ahmed Z, Ahmed U, Walayat S, Ren J, Martin DK, Moole H, Koppe S, Yong S, Dhillon S. Liver function tests in identifying patients with liver disease. Clin Exp Gastroenterol. 2018 Aug 23;11:301-307. https://doi.org/10.2147/CEG.S160537 PMid:30197529 PMCid:PMC6112813
62. Wazir H, Abid M, Essani B, Saeed H, Ahmad Khan M, Nasrullah F, Qadeer U, Khalid A, Varrassi G, Muzammil MA, Maryam A, Syed ARS, Shah AA, Kinger S, Ullah F. Diagnosis and Treatment of Liver Disease: Current Trends and Future Directions. Cureus. 2023 Dec 4;15(12):e49920. https://doi.org/10.7759/cureus.49920
63. Navarro VJ, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. Hepatology. 2017 Jan;65(1):363-373. https://doi.org/10.1002/hep.28813 PMid:27677775 PMCid:PMC5502701
64. Reau NS. The Importance of Making an Accurate Diagnosis for Hepatic Encephalopathy. Gastroenterol Hepatol (N Y). 2023 Dec;19(12):740-748.
65. Assy N, Jacob G, Spira G, Edoute Y. Diagnostic approach to patients with cholestatic jaundice. World J Gastroenterol. 1999 Jun;5(3):252-262. https://doi.org/10.3748/wjg.v5.i3.252 PMid:11819442 PMCid:PMC4688481
66. de Bruyn G, Graviss EA. A systematic review of the diagnostic accuracy of physical examination for the detection of cirrhosis. BMC Med Inform Decis Mak. 2001;1:6. https://doi.org/10.1186/1472-6947-1-6 PMid:11806763 PMCid:PMC64783
67. Bassari R, Koea JB. Jaundice associated pruritis: a review of pathophysiology and treatment. World J Gastroenterol. 2015 Feb 7;21(5):1404-13. https://doi.org/10.3748/wjg.v21.i5.1404 PMid:25663760 PMCid:PMC4316083
68. Hall P, Cash J. What is the real function of the liver 'function' tests? Ulster Med J. 2012 Jan;81(1):30-6.
69. Lala V, Zubair M, Minter DA. Liver Function Tests. 2023 Jul 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. PMID: 29494096.
70. Coenegrachts K. Magnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions. World J Radiol. 2009 Dec 31;1(1):72-85. https://doi.org/10.4329/wjr.v1.i1.72 PMid:21160723 PMCid:PMC2999307
71. Neuberger J, Patel J, Caldwell H, Davies S, Hebditch V, Hollywood C, Hubscher S, Karkhanis S, Lester W, Roslund N, West R, Wyatt JI, Heydtmann M. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. Gut. 2020 Aug;69(8):1382-1403. https://doi.org/10.1136/gutjnl-2020-321299 PMid:32467090 PMCid:PMC7398479
72. Wazir H, Abid M, Essani B, Saeed H, Ahmad Khan M, Nasrullah F, Qadeer U, Khalid A, Varrassi G, Muzammil MA, Maryam A, Syed ARS, Shah AA, Kinger S, Ullah F. Diagnosis and Treatment of Liver Disease: Current Trends and Future Directions. Cureus. 2023 Dec 4;15(12):e49920. https://doi.org/10.7759/cureus.49920
73. Mondal M, Sarkar C, Saha S, Hossain MN, Norouzi R, Mubarak MS, Siyadatpanah A, Wilairatana P, Hossain R, Islam MT, Coutinho HDM. Hepatoprotective activity of andrographolide possibly through antioxidative defense mechanism in Sprague-Dawley rats. Toxicol Rep. 2022 Apr 22;9:1013-1022. https://doi.org/10.1016/j.toxrep.2022.04.007 PMid:36518448 PMCid:PMC9742837
74. Satheesh Naik K, Gurushanthaiah M, Kavimani M, Prabhu K, Lokanadham S. Hepatoprotective Role of Eclipta alba against High Fatty Diet Treated Experimental Models - A Histopathological Study. Maedica (Bucur). 2018 Sep;13(3):217-222. doi: https://doi.org/10.26574/maedica.2018.13.3.217 .
75. Verma PC, Basu V, Gupta V, Saxena G, Rahman LU. Pharmacology and chemistry of a potent hepatoprotective compound Picroliv isolated from the roots and rhizomes of Picrorhiza kurroa royle ex benth. (kutki). Curr Pharm Biotechnol. 2009 Sep;10(6):641-9. https://doi.org/10.2174/138920109789069314 PMid:19619118
76. Das S, Singh PK, Ameeruddin S, Kumar Bindhani B, Obaidullah WJ, Obaidullah AJ, Mishra S, Mohapatra RK. Ethnomedicinal values of Boerhaavia diffusa L. as a panacea against multiple human ailments: a state of art review. Front Chem. 2023 Nov 14;11:1297300. https://doi.org/10.3389/fchem.2023.1297300 PMid:38033469 PMCid:PMC10682173
77. Abu Hassan MR, Hj Md Said R, Zainuddin Z, Omar H, Md Ali SM, Aris SA, Chan HK. Effects of one-year supplementation with Phyllanthus niruri on fibrosis score and metabolic markers in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Heliyon. 2023 May 30;9(6):e16652. https://doi.org/10.1016/j.heliyon.2023.e16652 PMid:37313177 PMCid:PMC10258366
78. Ionita-Radu F, Patoni C, Nancoff AS, Marin FS, Gaman L, Bucurica A, Socol C, Jinga M, Dutu M, Bucurica S. Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature. Int J Mol Sci. 2024 Apr 10;25(8):4201. https://doi.org/10.3390/ijms25084201 PMid:38673787 PMCid:PMC11050387
79. Zhang H, Lv JL, Zheng QS, Li J. Active components of Solanum nigrum and their antitumor effects: a literature review. Front Oncol. 2023 Dec 19;13:1329957. https://doi.org/10.3389/fonc.2023.1329957 PMid:38192621 PMCid:PMC10773844
80. Krepkova LV, Babenko AN, Lemyaseva SV, Saybel OL, Sherwin CM, Enioutina EY. Modulation of Hepatic Functions by Chicory (Cichorium intybus L.) Extract: Preclinical Study in Rats. Pharmaceuticals (Basel). 2023 Oct 16;16(10):1471. https://doi.org/10.3390/ph16101471 PMid:37895942 PMCid:PMC10609820
81. Ozbek H, Uğraş S, Dülger H, Bayram I, Tuncer I, Oztürk G, Oztürk A. Hepatoprotective effect of Foeniculum vulgare essential oil. Fitoterapia. 2003 Apr;74(3):317-9. https://doi.org/10.1016/S0367-326X(03)00028-5 PMid:12727504
82. Daneshvar-Ghahfarokhi S, Ahmadinia H, Sadeghi T, Basirat E, Mohammadi-Shahrokhi V. Achillea millefolium capsule improved liver enzymes and lipid profile compared to placebo in patients with type 2 diabetes: a double-blind randomized clinical trial. BMC Nutr. 2025 Jan 24;11(1):21. https://doi.org/10.1186/s40795-025-01005-5 PMid:39856724 PMCid:PMC11761196
83. Wang H, Zhang H, Zhang Y, Wang D, Cheng X, Yang F, Zhang Q, Xue Z, Li Y, Zhang L, Yang L, Miao G, Li D, Guan Z, Da Y, Yao Z, Gao F, Qiao L, Kong L, Zhang R. Plumbagin protects liver against fulminant hepatic failure and chronic liver fibrosis via inhibiting inflammation and collagen production. Oncotarget. 2016 Dec 13;7(50):82864-82875. https://doi.org/10.18632/oncotarget.12655 PMid:27756878 PMCid:PMC5347738
84. Maituoheti R, Rouzimaimaiti R, Tang D, Zhao J, Aisa HA. Seco-iridoid glycosides from the Gentiana olivieri Griseb and their bioactivities. Phytochemistry. 2023 Nov;215:113839. https://doi.org/10.1016/j.phytochem.2023.113839 PMid:37657663
85. Ibrahim M, Khaja MN, Aara A, Khan AA, Habeeb MA, Devi YP, Narasu ML, Habibullah CM. Hepatoprotective activity of Sapindus mukorossi and Rheum emodi extracts: in vitro and in vivo studies. World J Gastroenterol. 2008 Apr 28;14(16):2566-71. https://doi.org/10.3748/wjg.14.2566 PMid:18442207 PMCid:PMC2708371
86. Jung JC, Lee YH, Kim SH, Kim KJ, Kim KM, Oh S, Jung YS. Hepatoprotective effect of licorice, the root of Glycyrrhiza uralensis Fischer, in alcohol-induced fatty liver disease. BMC Complement Altern Med. 2016 Jan 22;16:19. https://doi.org/10.1186/s12906-016-0997-0 PMid:26801973 PMCid:PMC4722619
87. Urfi MK, Mujahid M, Rahman MA, Rahman MA. The Role of Tamarix gallica Leaves Extract in Liver Injury Induced by Rifampicin Plus Isoniazid in Sprague Dawley Rats. J Diet Suppl. 2018 Jan 2;15(1):24-33. https://doi.org/10.1080/19390211.2017.1310783 PMid:28459346
88. Oh GS, Yoon J, Lee GG, Kwak JH, Kim SW. The Hexane Fraction of cyperus rotundus Prevents Non-Alcoholic Fatty Liver Disease Through the Inhibition of Liver X Receptor α-Mediated Activation of Sterol Regulatory Element Binding Protein-1c. Am J Chin Med. 2015;43(3):477-494. https://doi.org/10.1142/S0192415X15500305 PMid:25967664
89. Batiha GE, Olatunde A, El-Mleeh A, Hetta HF, Al-Rejaie S, Alghamdi S, Zahoor M, Magdy Beshbishy A, Murata T, Zaragoza-Bastida A, Rivero-Perez N. Bioactive Compounds, Pharmacological Actions, and Pharmacokinetics of Wormwood (Artemisia absinthium). Antibiotics (Basel). 2020 Jun 23;9(6):353. https://doi.org/10.3390/antibiotics9060353 PMid:32585887 PMCid:PMC7345338
90. Gupta S, Ved A. Operculina turpethum (Linn.) Silva Manso as a Medicinal Plant Species: A Review on Bioactive Components and Pharmacological Properties. Pharmacogn Rev. 2017 Jul-Dec;11(22):158-166. https://doi.org/10.4103/phrev.phrev_6_17 PMid:28989252 PMCid:PMC5628523
91. Poojari R, Gupta S, Maru G, Khade B, Bhagwat S. Chemopreventive and hepatoprotective effects of embelin on N-nitrosodiethylamine and carbon tetrachloride induced preneoplasia and toxicity in rat liver. Asian Pac J Cancer Prev. 2010;11(4):1015-20.
92. Sharma V, Pandey D. Protective Role of Tinospora cordifolia against Lead-induced Hepatotoxicity. Toxicol Int. 2010 Jan;17(1):12-7. https://doi.org/10.4103/0971-6580.68343 PMid:21042467 PMCid:PMC2964743
93. Fahmi A, Hassanen N, Abdur-Rahman M, Shams-Eldin E. Phytochemicals, antioxidant activity and hepatoprotective effect of ginger (Zingiber officinale) on diethylnitrosamine toxicity in rats. Biomarkers. 2019 Jul;24(5):436-447. https://doi.org/10.1080/1354750X.2019.1606280 PMid:30979347
94. Haridevamuthu B, Seenivasan B, Priya PS, Muthuraman S, Kumar RS, Manikandan K, Almutairi BO, Almutairi MH, Arokiyaraj S, Gopinath P, Arockiaraj J. Hepatoprotective effect of dihydroxy piperlongumine in high cholesterol-induced non-alcoholic fatty liver disease zebrafish via antioxidant activity. Eur J Pharmacol. 2023 Apr 15;945:175605. https://doi.org/10.1016/j.ejphar.2023.175605 PMid:36822456
95. Jain M, Kapadia R, Jadeja RN, Thounaojam MC, Devkar RV, Mishra SH. Hepatoprotective potential of Tecomella undulata stem bark is partially due to the presence of betulinic acid. J Ethnopharmacol. 2012 Aug 30;143(1):194-200. https://doi.org/10.1016/j.jep.2012.06.023 PMid:22789967
96. Anonymous. The Ayurvedic Pharmacopoeia of India. Part-I, Vol-I.Government of India Ministry of Health and Family Welfare Department of Ayush. 1989.
97. Anonymous. The Unani Pharmacopoeia of India. Part-I, Vol-I-VII. Government of India Ministry of Health and Family Welfare Department of Ayush. 2007.
Published
Abstract Display: 744 
PDF Downloads: 614 PDF Downloads: 56 How to Cite
Issue
Section
Copyright (c) 2025 Md Anzar Alam, Barkati Md Tarique, Arvind Kumar, Raghavendara Kumar Sharma, Mohd Aleemuddin Quamri, Khalid Eqbal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.